Biotechnology News

Jean-Philippe Rocher Appointed Head of Pharmaceutical DevelopmentMikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October...

In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC  After agreement with the...

NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...

PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based...

PARIS et CAMBRIDGE, Mass., 01 oct. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique...

RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related...

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

Second FDA Fast Track designation expands oncology opportunity and supports expedited development across multiple cancer indications

PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month Validation confirms that the application is complete and EMA initiates formal review of...